Randomized Study of CX-01 Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
This was an exploratory Phase 2, open label, randomized, multicenter , parallel group study
to determine whether there was evidence that the addition of dociparstat (CX-01) at 2
different does levels to standard induction therapy (cytarabine+idarubicin, "7+3") and
consolidation therapy had an additive therapeutic effect for subjects newly diagnosed with
acute myeloid leukemia (AML) when compared with subjects receiving standard induction
chemotherapy alone.